Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment

Silvia Moga, Andreea Teodorescu, Petru Ifteni, Claudia Gavris, Paula-Simina Petric Faculty of Medicine, Transilvania University of Brasov, Brasov, RomaniaCorrespondence: Petru IfteniFaculty of Medicine, Transilvania University of Brasov, Romania, 29th Eroilor Boulevard, Brasov, 500036, RomaniaTel +4...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Moga S, Teodorescu A, Ifteni P, Gavris C, Petric PS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	schizophrenia covid-19 inflammation antipsychotics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/33bd9fde65da4172a7e308ba23ae9f60
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:33bd9fde65da4172a7e308ba23ae9f60
record_format	dspace
spelling	oai:doaj.org-article:33bd9fde65da4172a7e308ba23ae9f602021-12-02T17:18:26ZInflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment1178-2021https://doaj.org/article/33bd9fde65da4172a7e308ba23ae9f602021-10-01T00:00:00Zhttps://www.dovepress.com/inflammatory-response-in-sars-cov-2-infection-of-patients-with-schizop-peer-reviewed-fulltext-article-NDThttps://doaj.org/toc/1178-2021Silvia Moga, Andreea Teodorescu, Petru Ifteni, Claudia Gavris, Paula-Simina Petric Faculty of Medicine, Transilvania University of Brasov, Brasov, RomaniaCorrespondence: Petru IfteniFaculty of Medicine, Transilvania University of Brasov, Romania, 29th Eroilor Boulevard, Brasov, 500036, RomaniaTel +40 724 993329Email petru_ifteni@yahoo.comBackground: Schizophrenia patients are a population at particular risk of poor outcomes in COVID-19 infection. They have multiple comorbidities that have been identified as risk factors for severe COVID-19: diabetes, hypertension, chronic obstructive respiratory disease, and end-stage renal disease.Aim: The aim of this research was to evaluate the inflammatory response and in-hospital mortality in schizophrenia patients compared to a control group without mental illness.Methods: A total of 101 consecutive individuals with schizophrenia tested positive for COVID-19 was compared with 101 individuals without schizophrenia admitted in the same hospital. The number of severe cases and the number of deaths caused by SARS-CoV-2 were evaluated between April 2020 and April 2021.Results: There were no deaths in the group of patients with schizophrenia. Although the group had a higher number of cases with pulmonary and metabolic comorbidities, in the group with SCZ there were fewer severe cases compared to the control group. The values of some markers of inflammation (CRP and fibrinogen) were significantly lower in SCZ patients. The duration from infection to diagnosis and the start of symptomatic treatment was shorter for the group with SCZ (4.2± 3.2 vs 5.3± 4.6, p < 0.05).Conclusion: The main findings of the study were that vulnerable schizophrenia individuals on antipsychotic treatment showed a lower risk of SARS-CoV-2 severe infection and a likely better COVID-19 prognosis in a protective environment. Rapid access to specialists in case of need are factors that have determined the favorable evolution in a group considered high risk. It could be speculated that antipsychotics could play an important role in preventing SARS-CoV-2 severe manifestation and may exert protective effects against detrimental courses of COVID-19.Keywords: schizophrenia, COVID-19, inflammation, antipsychoticsMoga STeodorescu AIfteni PGavris CPetric PSDove Medical Pressarticleschizophreniacovid-19inflammationantipsychoticsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 3053-3060 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	schizophrenia covid-19 inflammation antipsychotics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	schizophrenia covid-19 inflammation antipsychotics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Moga S Teodorescu A Ifteni P Gavris C Petric PS Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
description	Silvia Moga, Andreea Teodorescu, Petru Ifteni, Claudia Gavris, Paula-Simina Petric Faculty of Medicine, Transilvania University of Brasov, Brasov, RomaniaCorrespondence: Petru IfteniFaculty of Medicine, Transilvania University of Brasov, Romania, 29th Eroilor Boulevard, Brasov, 500036, RomaniaTel +40 724 993329Email petru_ifteni@yahoo.comBackground: Schizophrenia patients are a population at particular risk of poor outcomes in COVID-19 infection. They have multiple comorbidities that have been identified as risk factors for severe COVID-19: diabetes, hypertension, chronic obstructive respiratory disease, and end-stage renal disease.Aim: The aim of this research was to evaluate the inflammatory response and in-hospital mortality in schizophrenia patients compared to a control group without mental illness.Methods: A total of 101 consecutive individuals with schizophrenia tested positive for COVID-19 was compared with 101 individuals without schizophrenia admitted in the same hospital. The number of severe cases and the number of deaths caused by SARS-CoV-2 were evaluated between April 2020 and April 2021.Results: There were no deaths in the group of patients with schizophrenia. Although the group had a higher number of cases with pulmonary and metabolic comorbidities, in the group with SCZ there were fewer severe cases compared to the control group. The values of some markers of inflammation (CRP and fibrinogen) were significantly lower in SCZ patients. The duration from infection to diagnosis and the start of symptomatic treatment was shorter for the group with SCZ (4.2± 3.2 vs 5.3± 4.6, p < 0.05).Conclusion: The main findings of the study were that vulnerable schizophrenia individuals on antipsychotic treatment showed a lower risk of SARS-CoV-2 severe infection and a likely better COVID-19 prognosis in a protective environment. Rapid access to specialists in case of need are factors that have determined the favorable evolution in a group considered high risk. It could be speculated that antipsychotics could play an important role in preventing SARS-CoV-2 severe manifestation and may exert protective effects against detrimental courses of COVID-19.Keywords: schizophrenia, COVID-19, inflammation, antipsychotics
format	article
author	Moga S Teodorescu A Ifteni P Gavris C Petric PS
author_facet	Moga S Teodorescu A Ifteni P Gavris C Petric PS
author_sort	Moga S
title	Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
title_short	Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
title_full	Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
title_fullStr	Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
title_full_unstemmed	Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
title_sort	inflammatory response in sars-cov-2 infection of patients with schizophrenia and long-term antipsychotic treatment
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/33bd9fde65da4172a7e308ba23ae9f60
work_keys_str_mv	AT mogas inflammatoryresponseinsarscov2infectionofpatientswithschizophreniaandlongtermantipsychotictreatment AT teodorescua inflammatoryresponseinsarscov2infectionofpatientswithschizophreniaandlongtermantipsychotictreatment AT iftenip inflammatoryresponseinsarscov2infectionofpatientswithschizophreniaandlongtermantipsychotictreatment AT gavrisc inflammatoryresponseinsarscov2infectionofpatientswithschizophreniaandlongtermantipsychotictreatment AT petricps inflammatoryresponseinsarscov2infectionofpatientswithschizophreniaandlongtermantipsychotictreatment
_version_	1718381078646882304

Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment

Ejemplares similares